Ganirelix Acetate Injection

When receiving COS treatment, patients need to undergo controlled ovarian hyperstimulation with medication to obtain multiple mature ovums for assisted reproductive technologies such as in vitro fertilization (IVF). However, if LH peak appears too early during ovulation induction, it can lead to premature luteinization and ovulation of follicles, resulting in a decrease in the number and quality of ovums obtained, thereby affecting the success rate of assisted reproductive therapy.

Being able to competitively block GnRH receptors on pituitary gonadotropin cells, inhibit LH secretion, avoid premature LH peaks, ensure synchronous and full development of multiple follicles, and create conditions for obtaining high-quality ovums.

For example, in IVF technology, patients usually start using FSH for ovulation induction treatment on the second or third day of their menstrual cycle.

Based on the ovarian response, such as the number and size of growing and developing follicles, as well as the level of estradiol in the peripheral blood circulation, daily subcutaneous injection of acetic acid plus nifedipine (0.25mg) starting from the 5th or 6th day after FSH treatment can effectively prevent the occurrence of premature LH peaks.Due to its half-life, the time interval between two injections and the time interval between the last injection and hCG injection should not exceed 30 hours, otherwise premature LH peaks may occur.

If medication is taken in the morning, starting from the 5th or 6th day of FSH ovarian stimulation, administer acetic acid ganciclovir and continue the entire FSH treatment process until the day of ovulation induction (including the day of ovulation induction).If taking medication at night, start from the 5th day of ovarian stimulation and continue the entire FSH treatment process until the night before ovulation induction. The related study 38607 evaluated the safety and efficacy of acetic acid ganrelic in European women receiving controlled ovarian stimulation, using the Busherelin long regimen as a control group.

A total of 701 subjects were included in the intention to treat population (463 in the acetic acid group and 238 in the busherelin group). The main selection criteria are age 18-39 years old, body mass index between 18-29kg/m ², and menstrual cycle within the normal range of 24 to 35 days.The acetic acid ganrelic group started subcutaneous injection of acetic acid ganrelic (0.25mg/day) on the 6th day of FSH treatment until the day of receiving hCG (including that day);The Busherelin group started receiving treatment (0.6mg/day, administered via nasal route) from the 21st to the 24th day of the menstrual cycle.

After 14 days, if a decrease in regulation (E2 ≤ 50pg/mL) was reached, FSH treatment was initiated until the day of hCG treatment. The main efficacy indicator is the number of oocytes obtained on the day of ovum retrieval. Calculated per initiation cycle, the average number of oocytes obtained by subjects in the acetic acid garenicol group was 8.7, while that in the busherelin group was 9.7. The lower limit of the 97.5% confidence interval for the difference was -1.8. The results of this study and other similar studies indicate that acetic acid garenicol is significantly effective in preventing LH peaks.

Ovarian hyperstimulation syndrome is one of the common complications in assisted reproductive technology, mainly manifested as ovarian enlargement, ascites, pleural effusion, blood concentration, electrolyte imbalance, etc. In severe cases, ganirelix acetate injection can be life-threatening. The use of ovulation inducing drugs is one of the important causes of OHSS, as these drugs stimulate the ovaries, causing multiple follicles to develop simultaneously, resulting in increased ovarian volume and elevated estrogen levels.

By regulating hormne levels in the body, the stimulation of the ovaries by ovulation inducing drugs can be reduced, thereby lowering the risk of OHSS. Continuing to use acetic acid garenicol after ovum retrieval can further reduce ovarian stimulation response and help patients recover. For example, clinical trials have shown that compared to the use of GnRH agonists, their use can reduce the incidence of OHSS, decrease patient discomfort and complications caused by OHSS, and improve the safety and comfort of treatment.

Taking into account the above effects, the success rate of treatment can be significantly improved in assisted reproductive technology.

By preventing premature LH peak, promoting ovulation, improving ovum quality, and reducing OHSS, favorable conditions have been created for obtaining high-quality ovums and embryos, increasing the chances of conception. At the same time, the treatment process has been optimized, the occurrence of complications has been reduced, and the patient's treatment experience and compliance have been improved.